Skip to Content

Emsam Approved - Bristol-Myers Squibb Company/Somerset Pharmaceuticals, Inc. - Treatment for Major Depressive Disorder

Emsam is a transdermal patch containing the monoamine oxidase inhibitor selegiline. Emsam is indicated for the treatment of major depressive disorder (MDD) in adults.

Posted: February 2006

Related Articles:

Emsam (selegiline) FDA Approval History

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of in your inbox.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.